To include your compound in the COVID-19 Resource Center, submit it here.

Federal judge invalidates four Restasis patents, slams Allergan's patent deal with tribe

On Oct. 16, a federal judge invalidated four patents covering dry-eye drug Restasis cyclosporine Allergan plc (NYSE:AGN) and questioned the pharma's patent deal with the Saint Regis Mohawk Tribe. Although the court found that Allergan proved its case that a handful of generic drug companies infringed on its patents,

Read the full 498 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers